Protocol Development and Quality Improvement

Sciences; January 5–8, 2009; Washington DC. Accessed

May 1, 2025. https://orchid.cs.illinois.edu/publications/

HICSS-idea-generation-2009.pdf

Institute for Healthcare Improvement (IHI). Failure

Modes and Effects Analysis (FMEA) Tool. Accessed

May

1,

2025.

https://www.ihi.org/resources/tools/

failure-modes-and-effects-analysis-fmea-tool

Institute for Safe Medical Practices (ISMP). ISMP targeted

medication safety best practices for hospitals (2020–

2021). Accessed May 1, 2025. https://www.ismp.org/

sites/default/files/attachments/2020-02/2020-2021%20

TMSBP-%20FINAL_1.pdf

The consensus of the Pharmacy Practice Model

1152. https://doi.org/10.2146/ajhp110060

The Joint Commission (TJC). Performance measurement.

Accessed May 1, 2025. https://www.jointcommission.

org/measurement/

Varkey P, Reller MK, Resar RK. Basics of qual-

ity improvement in health care.  Mayo Clin Proc.

2007;82(6):735-739. https://doi.org/10.4065/82.6.735

Medication Use Evaluation

American Society of Health-System Pharmacists

(ASHP). ASHP guidelines on medication-use evalu-

ation. Accessed May 1, 2025. https://www.ashp.org/-/

media/assets/policy-guidelines/docs/guidelines/medica-

tion-use-evaluation-current.ashx

Documentation of Pharmacy Services

Andrawis M, Ellison LTCC, Riddle S, et al.

Recommended quality measures for health-system phar-

macy: 2019 update from the Pharmacy Accountability

2019;76(12):874-887. https://doi.org/10.1093/ajhp/zxz069

Brilli RJ, Spevetz A, Branson RD, et al. Critical

care delivery in the intensive care unit: defin-

ing clinical roles and the best practice model.  Crit

Care

Med.

2001;29(10):2007-2019.

https://doi.

org/10.1097/00003246-200110000-00026

Cassat S, Massey L, Buckingham S, Kemplay T,

Little J. Development of health-system inpatient phar-

2019;76(23):1958-1964.

https://doi.org/10.1093/ajhp/

zxz225

Dager W, Bolesta S, Brophy G, et al. An opinion paper

outlining recommendations for training, credentialing,

and documenting and justifying critical care pharmacy

doi.org/10.1592/phco.31.8.829

Horn E, Jacobi J. The critical care clinical pharmacist:

2006;34(3 Suppl):S46-S51. https://doi.org/10.1097/01.

ccm.0000199990.68341.33

Kane SL, Weber RJ, Dasta JF. The impact of critical care

pharmacists on enhancing patient outcomes.  Intensive

s00134-003-1705-3

Lat I, Paciullo C, Daley MJ, et al. Position paper on

Med.

2020;48(9):e813-e834.

https://doi.org/10.1097/

ccm.0000000000004437

Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist par-

ticipation on physician rounds and adverse drug events

https://doi.org/10.1001/jama.282.3.267

Montazeri M, Cook DJ. Impact of a clinical phar-

macist in a multidisciplinary intensive care unit.  Crit

Care

Med.

1994;22(6):1044-1048.

https://doi.

org/10.1097/00003246-199406000-00027

Overhage JM, Lukes A. Practical, reliable, comprehen-

sive method for characterizing pharmacists’ clinical

2450. https://doi.org/10.1093/ajhp/56.23.2444

Patanwala AE, Narayan SW, Haas CE, Abraham I,

Sanders A, Erstad BL. Proposed guidance on cost-avoid-

Pharm. 2021;78(17):1559-1567. https://doi.org/10.1093/

ajhp/zxab211

Pawloski P, Cusick D, Amborn L. Development of

Syst Pharm. 2012;69(1):49-54. https://doi.org/10.2146/

ajhp110126

Preslaski CR, Lat I, MacLaren R, Poston J. Pharmacist

contributions as members of the multidisciplinary

ICU team.  Chest. 2013;144(5):1687-1695. https://doi.

org/10.1378/chest.12-1615